Fox Chase Cancer Center's Daly Promoted to Senior Member
PHILADELPHIA (November 29, 2000) — Dr. Mary B. Daly, a medical oncologist and epidemiologist, has been promoted to senior member of the population science division of Fox Chase Cancer Center. Daly, who lives in Stockton, N.J., joined the Center in 1989. She is a leading national authority on medical and ethical issues concerning familial cancer syndromes and the identification and communication of cancer risk, said Dr. Paul F. Engstrom, senior vice president for population science, when he announced her promotion.
Daly initiated the Margaret Dyson Family Risk Assessment Program at Fox Chase to help women cope with an increased risk of breast or ovarian cancer. The program, which is still directed by Daly, was among the first of its kind and the only one in the region when it opened in 1991. It has become a model for risk assessment programs in cancer centers around the country.
Daly's work in breast cancer prevention is nationally recognized. She was principal investigator at Fox Chase for the first national Breast Cancer Prevention Trial, a clinical study designed to find out if the drug tamoxifen can prevent breast cancer in women at high risk of the disease. She is also principal investigator for a new breast cancer prevention study, which began in May 1999. This trial, a Study of Tamoxifen and Raloxifene (STAR), will compare the effectiveness of two drugs.
Before joining Fox Chase, Daly was stationed at Wilford Hall Medical Center, Lackland Air Force Base, Texas, where she held the rank of lieutenant colonel. As chief of hematology and medical oncology there, Daly started the first bone-marrow transplant program operated by the Department of Defense.
Daly is the president-elect of the American Society of Preventive Oncology. She is a fellow of the American College of Physicians and a member of the American Association of Cancer Research, American Society of Clinical Oncology, American College of Epidemiology, American Association of Cancer Education and several other professional organizations. In 1995 she was appointed to the Board of Scientific Advisors for the National Cancer Institute.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.